BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, Sugawara Y, Nakagawa N, Tani Y, Wada J, Sugiyama H, Tsuruya K, Nakano T, Maruyama S, Wada T, Yamagata K, Narita I, Tamura K, Yanagita M, Terada Y, Shigematsu T, Sofue T, Ito T, Okada H, Nakashima N, Kataoka H, Ohe K, Okada M, Itano S, Nishiyama A, Kanda E, Ueki K, Kashihara N. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care 2021;44:2542-51. [PMID: 34593566 DOI: 10.2337/dc21-1081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Sato K, Terauchi Y, Tamura K, Kanamori A. Comparison of the blood pressure management between sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Sci Rep 2022;12:16106. [PMID: 36167964 DOI: 10.1038/s41598-022-20313-5] [Reference Citation Analysis]
2 Shibata R, Taguchi K, Kaida Y, Fukami K. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus. Clin Exp Nephrol. [DOI: 10.1007/s10157-022-02277-y] [Reference Citation Analysis]
3 Takahashi T, Watanabe T, Aono T, Otaki Y, Wanezaki M, Nishiyama S, Kutsuzawa D, Kato S, Tamura H, Arimoto T, Takahashi H, Watanabe M. Prognostic Impact of Renal Dysfunction at 1-Year Follow-Up on Clinical Outcomes After Percutaneous Coronary Intervention. J Atheroscler Thromb 2022. [PMID: 36123047 DOI: 10.5551/jat.63746] [Reference Citation Analysis]
4 Suzuki Y, Kaneko H, Okada A, Matsuoka S, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Node K, Nangaku M, Yasunaga H, Komuro I. Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium-glucose cotransporter-2 inhibitors. Kidney Int 2022:S0085-2538(22)00510-5. [PMID: 35961884 DOI: 10.1016/j.kint.2022.05.031] [Reference Citation Analysis]
5 Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, Santulli G. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension 2022;79:1633-43. [PMID: 35703100 DOI: 10.1161/HYPERTENSIONAHA.122.19586] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
6 Kurata Y, Nangaku M. Dapagliflozin for the treatment of chronic kidney disease. Expert Review of Endocrinology & Metabolism. [DOI: 10.1080/17446651.2022.2099373] [Reference Citation Analysis]
7 Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M, Bokuda K, Ichihara A, Nozato Y, Toba A, Narita K, Hoshide S, Tanaka A, Node K, Yoshida Y, Shibata H, Katsurada K, Kuwabara M, Kodama T, Shinohara K, Kario K. Update on Hypertension Research in 2021. Hypertens Res 2022. [PMID: 35790879 DOI: 10.1038/s41440-022-00967-4] [Reference Citation Analysis]
8 Lin W, Luo Y, Liu F, Li H, Wang Q, Dong Z, Chen X. Status and Trends of the Association Between Diabetic Nephropathy and Diabetic Retinopathy From 2000 to 2021: Bibliometric and Visual Analysis. Front Pharmacol 2022;13:937759. [DOI: 10.3389/fphar.2022.937759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Au PCM, Tan KCB, Cheung BMY, Wong ICK, Li HL, Cheung CL. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes. J Clin Endocrinol Metab 2022;107:e2962-70. [PMID: 35303075 DOI: 10.1210/clinem/dgac164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Sasako T, Yamauchi T. Addressing screams for evidence on renoprotection by GLP-1 receptor agonists. Kidney International 2022;101:222-4. [DOI: 10.1016/j.kint.2021.11.021] [Reference Citation Analysis]
11 Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, Kimura M, Saito N, Kanaoka T, Aoyama T, Umezono T, Ito S, Suzuki D, Takeda H, Minagawa F, Degawa H, Machimura H, Hishiki T, Umezawa S, Shimura H, Nakajima S, Yamamoto H, Sato K, Miyakawa M, Terauchi Y, Tamura K, Kanamori A. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Research and Clinical Practice 2022. [DOI: 10.1016/j.diabres.2022.109231] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Iwagami M, Shinozaki T. Introduction to Matching in Case-Control and Cohort Studies. ACE 2022;4:33-40. [DOI: 10.37737/ace.22005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]